查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600089

GLP-1 受體促效劑市場：按藥物類型、給藥途徑、分銷管道和應用分類 - 全球預測 2025-2030

GLP-1 Receptor Agonist Market by Drug Type (Albiglutide, Dulaglutide, Exenatide), Route of Administration (Oral, Parenteral), Distribution Channel, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

GLP-1受體促效劑市場2023年估值為175.3億美元，預計2024年將達到189.2億美元，複合年成長率為8.18%，2030年將達到304億美元，預計將達到1000萬美元。

GLP-1受體促效劑是一類主要用於透過刺激胰島素分泌和抑制升糖素釋放來控制第二型糖尿病的藥物，從而增強血糖控制。最近，由於其抑制食慾的作用，也有望用於體重管理。全球糖尿病盛行率不斷上升，推動了對 GLP-1 受體促效劑的需求，糖尿病通常與肥胖有關，需要先進的治療方案。 GLP-1受體促效劑的用途不僅限於糖尿病管理，它們作為肥胖和心血管疾病治療藥物的潛力也越來越被認知到。這些促效劑的最終用途包括醫療保健提供者、糖尿病專家、體重管理診所等。市場洞察顯示，由於糖尿病患者人數不斷增加、肥胖率上升，以及人們越來越意識到胰島素相對於傳統胰島素療法的益處，需求正在激增。藥物配方和遞送方法的技術進步和持續的研究努力進一步推動了市場的成長。個人化醫療（專注於以患者為中心的藥物機制）以及糖尿病盛行率迅速增加的不斷擴大的地域市場也出現了機會。然而，市場並非沒有挑戰。高昂的藥品成本、潛在的副作用和嚴格的監管環境是主要障礙。智慧財產權和專利懸崖是可能影響市場流動性的額外考慮因素。最佳創新領域包括開發口服製劑以提高患者依從性、具有擴大作用的生物合成藥物變化以及數位健康解決方案（例如用於提高患者依從性和結果的監測應用程式）。競爭格局的特點是生物相似藥產品的策略聯盟、收購和進步。企業應利用與研究機構的合作研究機會，並專注於具有成本效益的生產策略，以解決與成本相關的消費者猶豫。市場的本質是動態的，不斷的技術創新和不斷變化的消費者期望使市場保持競爭力，並為對世界新興醫療趨勢敏感的相關人員帶來希望。

主要市場統計
基準年[2023] 175.3億美元
預測年份 [2024] 189.2億美元
預測年份 [2030] 304.1億美元
複合年成長率（%） 8.18%

市場動態：快速發展的 GLP-1 受體促效劑市場的關鍵市場洞察

GLP-1 受體促效劑市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 糖尿病和肥胖症在全球增加
    • 政府措施和增加的醫療保健支出
  • 市場限制因素
    • 治療費用高，副作用大，例如胃腸道疾病和胰臟炎的潛在風險
  • 市場機會
    • 藥物輸送系統的進步可提高病患用藥依從性和便利性
    • 策略合作與聯盟加速研發
  • 市場挑戰
    • 未能堅持注射方案來增強藥物的治療效果

波特五力：駕馭 GLP-1 受體促效劑市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 GLP-1 受體促效劑市場的外部影響

外部宏觀環境因素在塑造 GLP-1 受體促效劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解 GLP-1 受體促效劑市場的競爭格局

GLP-1 受體促效劑市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 GLP-1 受體促效劑市場供應商的績效評估

FPNV定位矩陣是評估GLP-1受體促效劑市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製 GLP-1 受體促效劑市場的成功之路

GLP-1 受體促效劑市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 糖尿病和肥胖症在全球增加
      • 政府措施和不斷上漲的醫療成本
    • 抑制因素
      • 治療費用昂貴，並且有副作用，例如胃腸道不適和潛在的胰臟炎風險。
    • 機會
      • 藥物輸送系統的進步提高了病患的依從性和便利性
      • 策略合作和夥伴關係以加速研發
    • 任務
      • 注射時間表對藥物治療效果的依從性差
  • 市場區隔分析
    • 產品：提高人們對 GLP-1 受體促效劑顯著減重功效的認知
    • 應用：增加 GLP-1 在第 2 型糖尿病治療的應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 GLP-1 受體促效劑市場（依藥物類型）

  • albiglutide
  • Dulaglutide
  • Exenatide
  • Liraglutide
  • Semaglutide

第 7 章 GLP-1 受體促效劑市場：依給藥途徑

  • 口服
  • 胃腸外的

第 8 章 GLP-1促效劑市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第 9 章 GLP-1 受體促效劑市場：依應用分類

  • 肝硬化
  • 非酒精性脂肪性肝炎
  • 肥胖
  • 2型糖尿病

第10章美洲GLP-1受體促效劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太GLP-1受體促效劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲GLP-1受體促效劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 德國CDMO Corden Pharma投資9.8億美元擴大GLP-1產能
    • 輝瑞推進口服 GLP-1 受體促效劑的開發，用於治療第 2 型糖尿病
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • AstraZeneca Inc.
  • Bachem AG
  • Biopharma PEG
  • Boehringer Ingelheim International GmbH
  • Calibrate Health, Inc.
  • Cleveland Clinic
  • Daiichi Sankyo Company, Limited
  • Diabetes UK
  • Eli Lilly and Company
  • GenScript
  • GlaxoSmithKline plc
  • GOODRX HOLDINGS, INC.
  • Hanmi Pharm.Co.,Ltd.
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Patsnap（UK）Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Twist Bioscience Corporation
  • WebMD LLC.
Product Code: MRR-B9334AD6C5EF

The GLP-1 Receptor Agonist Market was valued at USD 17.53 billion in 2023, expected to reach USD 18.92 billion in 2024, and is projected to grow at a CAGR of 8.18%, to USD 30.41 billion by 2030.

GLP-1 Receptor Agonists are a class of medications primarily used in managing type 2 diabetes by enhancing glycemic control through stimulating insulin secretion and inhibiting glucagon release. They have recently gained traction due to their potential in weight management, given their appetite-suppressing properties. The necessity of GLP-1 receptor agonists stems from the global rise in diabetes prevalence, often linked to obesity, necessitating advanced therapeutic options. Their application spans beyond diabetes management, as they are increasingly recognized in potentially treating obesity and cardiovascular diseases. The end-use scope of these agonists largely includes healthcare providers, diabetes specialists, and weight management clinics. Market insights reveal burgeoning demand due to rising diabetes cases, increased obesity rates, and growing awareness of the benefits over traditional insulin therapy. Technological advancements and consistent research efforts in drug formulations and delivery methods further fuel market growth. Opportunities are emerging in personalized medicine, with a focus on patient-centric drug mechanisms, and in expanding geographical markets where diabetes prevalence is rapidly increasing. However, the market is not without challenges; high drug costs, potential side effects, and stringent regulatory landscapes pose significant barriers. Intellectual property rights and patent cliffs are additional considerations that can affect market fluidity. Best areas for innovation include developing oral formulations to enhance patient compliance, biosynthetic drug variations with extended action, and integration with digital health solutions, like monitoring applications, for improved patient adherence and outcomes. The competitive landscape is characterized by strategic collaborations, acquisitions, and advancements in biosimilar products. Businesses should capitalize on collaboration opportunities with research institutions and focus on cost-effective production tactics to address cost-related consumer hesitancies. The nature of the market is dynamic, with continual innovations and evolving consumer expectations keeping it both competitive and promising for stakeholders attuned to emerging global health trends.

KEY MARKET STATISTICS
Base Year [2023] USD 17.53 billion
Estimated Year [2024] USD 18.92 billion
Forecast Year [2030] USD 30.41 billion
CAGR (%) 8.18%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving GLP-1 Receptor Agonist Market

The GLP-1 Receptor Agonist Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Global rise in the prevalence of diabetes and obesity
    • Increasing government initiatives and healthcare expenditure
  • Market Restraints
    • High cost of treatment and adverse side effects such as gastrointestinal issues and potential risk of pancreatitis
  • Market Opportunities
    • Advancements in drug delivery systems to improve patient adherence and convenience
    • Strategic collaborations and alliances to accelerate the research and development
  • Market Challenges
    • Poor adherence to the injection regimen for the therapeutic efficacy of drugs

Porter's Five Forces: A Strategic Tool for Navigating the GLP-1 Receptor Agonist Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the GLP-1 Receptor Agonist Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the GLP-1 Receptor Agonist Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the GLP-1 Receptor Agonist Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the GLP-1 Receptor Agonist Market

A detailed market share analysis in the GLP-1 Receptor Agonist Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the GLP-1 Receptor Agonist Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the GLP-1 Receptor Agonist Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the GLP-1 Receptor Agonist Market

A strategic analysis of the GLP-1 Receptor Agonist Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the GLP-1 Receptor Agonist Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca Inc., Bachem AG, Biopharma PEG, Boehringer Ingelheim International GmbH, Calibrate Health, Inc., Cleveland Clinic, Daiichi Sankyo Company, Limited, Diabetes UK, Eli Lilly and Company, GenScript, GlaxoSmithKline plc, GOODRX HOLDINGS, INC., Hanmi Pharm.Co.,Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Patsnap (UK) Ltd., Pfizer Inc, Sanofi SA, Sun Pharmaceutical Industries Ltd., Twist Bioscience Corporation, and WebMD LLC..

Market Segmentation & Coverage

This research report categorizes the GLP-1 Receptor Agonist Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Albiglutide, Dulaglutide, Exenatide, Liraglutide, and Semaglutide.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Application, market is studied across Liver Cirrhosis, Non-Alcoholic Steatohepatitis, Obesity, and Type 2 Diabetes Mellitus.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Global rise in the prevalence of diabetes and obesity
      • 5.1.1.2. Increasing government initiatives and healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and adverse side effects such as gastrointestinal issues and potential risk of pancreatitis
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in drug delivery systems to improve patient adherence and convenience
      • 5.1.3.2. Strategic collaborations and alliances to accelerate the research and development
    • 5.1.4. Challenges
      • 5.1.4.1. Poor adherence to the injection regimen for the therapeutic efficacy of drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing awareness about the significant weight loss benefits offered by GLP-1 receptor agonists
    • 5.2.2. Application: Rising usage of GLP-1 in the management of type 2 diabetes mellitus
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. GLP-1 Receptor Agonist Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Albiglutide
  • 6.3. Dulaglutide
  • 6.4. Exenatide
  • 6.5. Liraglutide
  • 6.6. Semaglutide

7. GLP-1 Receptor Agonist Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. GLP-1 Receptor Agonist Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. GLP-1 Receptor Agonist Market, by Application

  • 9.1. Introduction
  • 9.2. Liver Cirrhosis
  • 9.3. Non-Alcoholic Steatohepatitis
  • 9.4. Obesity
  • 9.5. Type 2 Diabetes Mellitus

10. Americas GLP-1 Receptor Agonist Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific GLP-1 Receptor Agonist Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa GLP-1 Receptor Agonist Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. German CDMO Corden Pharma invests USD 980 million to expand GLP-1 manufacturing capacity
    • 13.3.2. Pfizer Advances Development of Oral GLP-1 Receptor Agonist for Type 2 Diabetes
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AstraZeneca Inc.
  • 3. Bachem AG
  • 4. Biopharma PEG
  • 5. Boehringer Ingelheim International GmbH
  • 6. Calibrate Health, Inc.
  • 7. Cleveland Clinic
  • 8. Daiichi Sankyo Company, Limited
  • 9. Diabetes UK
  • 10. Eli Lilly and Company
  • 11. GenScript
  • 12. GlaxoSmithKline plc
  • 13. GOODRX HOLDINGS, INC.
  • 14. Hanmi Pharm.Co.,Ltd.
  • 15. Innovent Biologics, Inc.
  • 16. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 17. Merck & Co., Inc.
  • 18. Novo Nordisk A/S
  • 19. Oramed Pharmaceuticals Inc.
  • 20. Patsnap (UK) Ltd.
  • 21. Pfizer Inc
  • 22. Sanofi SA
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Twist Bioscience Corporation
  • 25. WebMD LLC.

LIST OF FIGURES

  • FIGURE 1. GLP-1 RECEPTOR AGONIST MARKET RESEARCH PROCESS
  • FIGURE 2. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLP-1 RECEPTOR AGONIST MARKET DYNAMICS
  • TABLE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ALBIGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIVER CIRRHOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY NON-ALCOHOLIC STEATOHEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY TYPE 2 DIABETES MELLITUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2023